Status:
COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
Lead Sponsor:
Novartis
Conditions:
Hypertension, Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with essential hypertension
- Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.
- Patients who are eligible and able to participate in the study
- Exclusion Criteria
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
839 Patients enrolled
Trial Details
Trial ID
NCT00219089
Start Date
November 1 2004
End Date
August 1 2005
Last Update
May 17 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Centers, Germany